Demographic and baseline characteristics in the overall study cohort and segregated with respect to treatment arm
| Characteristic | Study cohort (N=131) | MT (N=21) | IVT (N=110) | p1 Value | IVT +MT (N=53) | p2 Value |
|---|---|---|---|---|---|---|
| Age, median (IQR) | 70 (60–75) | 74 (66–78) | 69 (57–75) | 0.039 | 64 (51– 73) | 0.006 |
| Male, N (%) | 65 (50) | 9 (43) | 56 (51) | 0.49 | 24 (45) | 0.35 |
| Hypertension, N (%) | 76 (58) | 11 (52) | 65 (59) | 0.56 | 28 (53) | 0.97 |
| Diabetes, N (%) | 21 (16) | 4 (19) | 17 (15) | 0.68 | 8 (15) | 0.67 |
| Dyslipidemia, N (%) | 55 (42) | 6 (29) | 49 (45) | 0.17 | 24 (45) | 0.18 |
| Smoker, N (%) | 35 (27) | 1 (5) | 34 (31) | 0.01 | 19 (34) | 0.007 |
| Alcohol consumption >40 g/day, N (%) | 15 (11) | 0 (0) | 5 (4) | 0.15 | 3 (6) | 0.1 |
| Atrial fibrillation, N (%) | 41 (31) | 11 (52) | 30 (27) | 0.023 | 12 (23) | 0.013 |
| Ischemic cardiomyopathy, N (%) | 17 (13) | 5 (24) | 12 (11) | 0.11 | 5 (9) | 0.1 |
| Valve disease, N (%) | 20 (15) | 5 (24) | 8 (7) | 0.02 | 2 (4) | 0.008 |
| Previous stroke, N (%) | 16 (12) | 3 (14) | 13 (12) | 0.52 | 5 (9) | 0.79 |
| Previous antiplatelet treatment, N (%) | 26 (20) | 2 (10) | 24 (22) | 0.2 | 12 (23) | 0.19 |
| Previous anticoagulation therapy, N (%) | 23 (18) | 9 (43) | 14 (13) | 0.001 | 3 (5) | 0.001 |
| Baseline NIHSS, median (IQR) | 17 (12–20) | 19 (13–22) | 16 (11–20) | 0.03 | 17 (14–22) | 0.24 |
| Baseline NCCT-ASPECTS, median (IQR) | 9 (8–10) | 9 (8–10) | 9 (8–10) | 0.59 | 9 (8–10) | 0.56 |
| Baseline CTA-SI-ASPECTS, median (IQR) | 8 (6–9) | 6 (4–10) | 8 (6–9) | 0.21 | 7 (6–9) | 0.52 |
| Baseline glycemia, mg/dL, mean (SD) | 124 (31) | 124 (109–138) | 116 (105–133) | 0.94 | 114 (104–137) | 0.89 |
| Systolic BP, mm Hg, mean (SD) | 146 (23) | 140 (135–150) | 143 (131–160) | 0.74 | 144 (130–161) | 0.89 |
| Diastolic BP, mm Hg, mean (SD) | 81 (16) | 76 (70–95) | 80 (71–90) | 0.58 | 81 (75–92) | 0.80 |
| Time from symptom onset to IVT, min, median (IQR) | 140 (115–185) | NA | 135 (115–180) | – | 132 (110–173) | – |
| Time from symptom onset to groin puncture, min, median (IQR) | 250 (205–310) | 210 (168–257) | NA | – | 275 (225–345) | 0.02 |
ASPECTS, Alberta Stroke Program Early CT Score; BP, blood pressure; CTA, CT angiography; IVT, IV thrombolysis; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale; P1, comparison of primary MT vs IVT; P2, comparison of primary MT vs IVT+MT.